Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_assertion type Assertion NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_head.
- NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_assertion description "[VEGFR1, TGFBR1, PDGFRA, SSTR5, SSTR2A, and IGF1R exhibited the highest levels of expression in the largest percentages of PETs.Anticancer drugs BMS-754807 (selective for IGF1R/IR), 17-(allylamino)-17-demethoxygeldanamycin (17-AAG, targeting Hsp90), and axitinib (directed toward VEGFR1-3/PDGFRA-B/KIT) induced growth inhibition of human QGP-1 PET cells with IC50 values (nM) of 273, 723, and 743, respectively.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_provenance.
- NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_assertion evidence source_evidence_literature NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_provenance.
- NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_assertion SIO_000772 23211371 NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_provenance.
- NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_assertion wasDerivedFrom befree-20140225 NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_provenance.
- NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_assertion wasGeneratedBy ECO_0000203 NP321481.RA31LdbzGKY-w6A1qYNwXSAsTq4pkkBA2QosdMFRtQRH0130_provenance.